S. Thongprasert

发表

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

T. Mok, Yi-long Wu, S. Thongprasert, 2009, The New England journal of medicine.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

C. Gridelli, S. Thongprasert, E. Felip, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib in previously treated non-small-cell lung cancer.

Renato Martins, Andrea Bezjak, Dongsheng Tu, 2005, The New England journal of medicine.

Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?

S. Thongprasert, J. Douillard, M. Bertram, 2019, ESMO Open.

Treatment of advanced non-small cell lung cancer with vinorelbine in elderly Thai patients.

S. Thongprasert, Sirikul Sorraritchingchai, C. Charoentum, 2004, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

M. Ahn, Keunchil Park, S. Thongprasert, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand

S. Thongprasert, U. Permsuwan, 2017, Current medical research and opinion.

Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.

S. Thongprasert, C. Charoentum, S. Moonprakan, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy.

S. Thongprasert, J. Clinch, P. Sanguanmitra, 1999, Lung cancer.

Lung cancer working group report.

T. Mitsudomi, Keunchil Park, T. Mok, 2010, Japanese journal of clinical oncology.

Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.

S. Thongprasert, B. Chewaskulyong, 2004, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

An indirect comparison of bevacizumab plus cisplatin‐gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first‐line non‐squamous non‐small cell lung cancer in East Asia

M. Ahn, S. Thongprasert, S. Walzer, 2011, Asia-Pacific journal of clinical oncology.

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.

T. Mok, Yi-long Wu, S. Thongprasert, 2016, Lung cancer.

Cost‐utility and budget impact analyses of gefitinib in second‐line treatment for advanced non‐small cell lung cancer from Thai payer perspective

S. Thongprasert, U. Permsuwan, S. Tinmanee, 2012, Asia-Pacific journal of clinical oncology.

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.

T. Mok, Yi-long Wu, S. Thongprasert, 2017, Lung cancer.

Epidermal Growth Factor Receptor Mutation Testing in Thailand: A Cost-Utility Analysis.

S. Thongprasert, U. Permsuwan, Narumon Tanatip, 2014, Value in health regional issues.

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS).

T. Mok, Yi-long Wu, S. Thongprasert, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Kevin Carroll, Nick Thatcher, Alex Chang, 2005, The Lancet.

Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST).

Michael Thomas, S. Thongprasert, P. Sunpaweravong, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ifosfamide, epirubicin and cisplatin (IEP): another active combination for small cell lung cancer (SCLC).

S. Thongprasert, K. Jiamsriponges, 1993, Lung cancer.

BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

T. Mok, S. Thongprasert, B. Klughammer, 2012 .

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Associati

S. Thongprasert, J. Sham, Y. Sumitsawan, 1998 .

Preliminary report of the asian‐oceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma

S. Thongprasert, J. Sham, Y. Sumitsawan, 1998, Cancer.

Update on Anti-EGFR Targeted Therapy

S. Thongprasert, L. Wirth, 2009 .

Lung cancer and quality of life.

S. Thongprasert, 1998, Australian and New Zealand journal of medicine.

Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma.

S. Thongprasert, B. Chewaskulyong, C. Charoentum, 2007, World journal of gastroenterology.

Systemic candidiasis in cancer patients.

S. Thongprasert, G. Bodey, V. Fainstein, 1984, The American journal of medicine.

A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.

S. Thongprasert, C. Charoentum, B. Chewaskulyong, 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

Mutation Analysis at Tyrosine Kinase Domain of EGFR Gene of Lung Cancer Patients in The Upper Northern Thailand

S. Thongprasert, N. Lertprasertsuke, D. Kangwanpong, 2010 .

Update on Anti-EGFR Therapy

P. Fasching, S. Thongprasert, B. Ma, 2009, Journal of oncology.

Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.

S. Thongprasert, Y. Chao, H. Lim, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kaposi's sarcoma in rheumatic diseases.

S. Thongprasert, W. Louthrenoo, N. Kasitanon, 2003, Seminars in arthritis and rheumatism.

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial

S. Thongprasert, Chun-Ming Tsai, T. Hsia, 2011, Asia-Pacific journal of clinical oncology.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Masahiro Fukuoka, Haiyi Jiang, Kazuhiko Nakagawa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes – Exploratory Data From IPASS

T. Mok, Yi-long Wu, S. Thongprasert, 2011 .

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

S. Thongprasert, Chun-Ming Tsai, Pan‐Chyr Yang, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pivotal Role of Liquid Biopsy in Diagnosing, Managing and Monitoring Early and Advanced Stages of Lung Cancer among Asian Population

S. Thongprasert, S. Saenghirunvattana, N. Lertprasertsuke, 2018 .

MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized

N. Altorki, S. Thongprasert, J. Vansteenkiste, 2009 .

Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma

M. Kudo, S. Thongprasert, Yoon-Koo Kang, 2016, Hepatology.

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

T. Mok, Yi-long Wu, S. Thongprasert, 2015, Clinical Cancer Research.

Cost‐effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non‐small cell lung cancer

S. Thongprasert, B. Chewaskulyong, C. Ruengorn, 2011, Asia-Pacific journal of clinical oncology.

A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial

A. Bezjak, L. Seymour, S. Thongprasert, 2004 .

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.

Joon-Oh Park, D. Doval, S. Thongprasert, 2012, European journal of cancer.

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

V. Gebski, S. Thongprasert, D. Chu, 2013, Journal of the National Cancer Institute.

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study

S. Thongprasert, R. Gaafar, M. Schenker, 2019, Lung cancer management.

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

V. Gebski, I. Marschner, T. Mitsudomi, 2017, Journal of the National Cancer Institute.

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach

Jie Yang, M. Salto‐Tellez, J. Shih, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

BiomarkerAnalysesandFinalOverallSurvivalResultsFroma PhaseIII,Randomized,Open-Label,First-LineStudyofGefitinib VersusCarboplatin/PaclitaxelinClinicallySelectedPatientsWith AdvancedNon-Small-CellLungCancerinAsia(IPASS)

T. Mok, Yi-long Wu, S. Thongprasert, 2011 .

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study

S. Thongprasert, C. Watkins, R. Perng, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.

Jie Yang, T. Mok, Yi-long Wu, 2013, Lung cancer.

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Li Zhang, Hongming Pan, Chong-Jen Yu, 2013, The Lancet. Oncology.

Ask the Experts: EGFR mutation and non-small-cell lung cancer: EGFR test, cost and quality of life

S. Thongprasert, 2012 .

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.

G. Scagliotti, R. Govindan, J. Strausz, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kaposi[apos ]s sarcoma in rheumatic diseases

S. Thongprasert, W. Louthrenoo, N. Kasitanon, 2003 .

Resource Constraints as a Barrier to Lung Cancer Management: Developing Nations

S. Thongprasert, U. Permsuwan, 2014 .

Phase II trial of mitoguazone in patients with advanced head and neck cancer.

R. Wittes, N. Geller, S. Thongprasert, 1984, Cancer treatment reports.

Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer.

S. Thongprasert, J. Euathrongchit, Sirikul Sorraritchingchai, 2007, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

Prevalence and relationship between major depressive disorder and lung cancer: a cross-sectional study

S. Thongprasert, N. Maneeton, B. Maneeton, 2014, OncoTargets and therapy.

Jie Yang, Yi-long Wu, S. Thongprasert, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

Michael Thomas, S. Thongprasert, P. Sunpaweravong, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma (PIONEER).

S. Thongprasert, Chun-Ming Tsai, Pan‐Chyr Yang, 2012 .

Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.

D. Doval, S. Thongprasert, J. Yi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

WILLINGNESS TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL PUBLIC VALUES

S. Thongprasert, R. Sakulbumrungsil, N. Chaiyakunapruk, 2015, International Journal of Technology Assessment in Health Care.

Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF‐directed Agent for Advanced NSCLC

S. Thongprasert, M. Nicolson, R. Rosell, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A. Bezjak, L. Seymour, S. Thongprasert, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.

T. Mok, Yi-long Wu, S. Thongprasert, 2012 .

The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.

S. Thongprasert, Pan‐Chyr Yang, R. Soo, 2016, Lung cancer.

157P Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: A phase IV study

S. Thongprasert, R. Gaafar, A. Abdelaziz, 2018 .

Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients.

S. Thongprasert, K. Rau, S. Ye, 2010 .

Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.

S. Thongprasert, U. Permsuwan, Buntitabhon Sirichanchuen, 2020, Value in health regional issues.

Efficacy and Tolerability of Tropisetron in the Prevention of Cisplatin-induced Nausea and Vomiting in Advanced Non-small Cell Lung Cancer

S. Thongprasert, 2000, Acta oncologica.

Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer.

S. Thongprasert, S. Napapan, R. Cheewakriangkrai, 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

The role of chemotherapy in cholangiocarcinoma.

S. Thongprasert, S. Thongprasert, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries.

F. Hirsch, S. Thongprasert, N. Lertprasertsuke, 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).

M. Kudo, S. Thongprasert, Yoon-Koo Kang, 2015 .

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

S. Thongprasert, P. Sunpaweravong, B. Margono, 2009, The New England journal of medicine.

Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.

T. Mok, S. Thongprasert, N. Iannotti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

V. Gebski, S. Thongprasert, D. Chu, 2013, Journal of the National Cancer Institute.

Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.

S. Thongprasert, 2000, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

9005 Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

S. Thongprasert, P. Sunpaweravong, D. Ferry, 2009 .

Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?

S. Thongprasert, J. Douillard, M. Bertram, 2019, ESMO Open.

CA 19-9 in combination with abdominal CT scan for the diagnosis of mass-forming intrahepatic cholangiocarcinoma.

S. Thongprasert, H. Sriplung, N. Lertprasertsuke, 2014, Hepatic oncology.